ფარმაცია / PHARMACY

ნოდარ სულაშვილი

ფარმაცევტულ და ფარმაკოლოგიური მეცნიერებათა დოქტორი მედიცინაში, შოთა მესხიას ზუგდიდის სახელმწიფო უნივერსიტეტის ფარმაციის საბაკალავრო პროგრამის ხელმძღვანელი, შოთა მესხიას ზუგდიდის სახელმწიფო უნივერსიტეტის ფარმაკოლოგიის, კლინიკური ფარმაციისა და ფარმაკოთერაპიის მიმართულებით აფილირებული ასოცირებული პროფესორი, ზუგდიდი, საქართველო; თბილისის სახელმწიფო სამედიცინო უნივერსიტეტის სამეცნიერო კვლევითი უნარ-ჩვევების ცენტრის მოწვეული ლექტორი (მოწვეული პროფესორი); თბილისის სახელმწიფო სამედიცინო უნივერსიტეტის კლინიკური ფარმაკოლოგიის დეპარტამენტის მოწვეული ლექტორი; თბილისი, საქართველო; მხითარ ჰერაცის სახელობის ერევნის სახელმწიფო სამედიცინო უნივერსიტეტის ფარმაცევტული მენეჯმენტის დეპარტამენტის სამეცნიერო მკვლევარი და მოწვეული პროფესორი, ერევანი, სომხეთი.

ORCID 0000-0002-9005-8577;

ელ. ფოსტა: n.sulashvili@ug.edu.ge

ნატო ალავიძე

ფარმაცევტულ მეცნიერებათა დოქტორი, აკაკი წერეთლის სახელმწიფო უნივერსიტეტის მედიცინის ფაკულტეტის ფარმაციის დეპარტამენტის პროფესორი, ქუთაისი, საქართველო. შოთა მესხიას ზუგდიდის სახელმწიფო უნივერსიტეტის ფარმაციის საგანმანათლებლო პროგრამის ხელმძღვანელი, პროფესორი; აღმოსავლეთ ევროპის უნივერსიტეტის მედიცინის ფაკულტეტის დეკანი, პროფესორი, თბილისი, საქართველო

ORCID 0000-0001-6695-5924

მარიკა სულაშვილი

საოჯახო მედიცინის დოქტორი, თბილისის სახელმწიფო სამედიცინო უნივერსიტეტის მოლეკულური და სამედიცინო გენეტიკის დეპარტამენტის მოწვეული ლექტორი,

საქართველოს უნივერსიტეტის ბიოქიმიისა და მოლეკულური და სამედიცინო გენეტიკის მოწვეული პროფესორი, თბილისი, საქართველო.

სამეცნიერო დისკურსი კიბოს საწინააღმდეგო ახალი ვაქცინების მახასიათებლებზე: ინოვაციები, ფარმაკოლოგია, კლინიკური გამოყენება და მომავლის პერსპექტივები

აბსტრაქტი

კიბოს საწინააღმდეგო ახალი ვაქცინების განვითარება ონკოლოგიაში ერთ-ერთ ყველაზე პერსპექტიულ ინოვაციად ითვლება, რომელიც აერთიანებს იმუნოლოგიის, მოლეკულური ბიოლოგიის, ნანოტექნოლოგიისა, ფარმაციის, ფარმაკოლოგიისა და პერსონალიზებული მედიცინის მიღწევებს. ტრადიციული ქიმიოთერაპიული და რადიოთერაპიული სტრატეგიებისგან განსხვავებით, კიბოს საწინააღმდეგო ვაქცინები მიზნად ისახავს ორგანიზმის საკუთარი იმუნური სისტემის გააქტიურებასა გაძლიერებასა და დაცვას, რათა აღმოაჩინოს და გაანადგუროს მავნე უჯრედები, მინიმალიზებული გვერდითი ტოქსიკური ეფექტებით. უახლესი ინოვაციები მოიცავს პეპტიდებსა და პროტეინებზე დაფუძნებულ ვაქცინებს, დენდრიტური უჯრედების საფუძველზე შექმნილ ფორმულირებებს, ვირუსულ ვექტორულ პლატფორმებს და mRNA ვაქცინებს, რომლებიც უზრუნველყოფენ მაღალ მრავალფეროვნებას და სწრაფად ადაპტირების შესაძლებლობას ინდივიდუალური სიმსივნური ანტიგენების მიმართ. სიმსივნური იმუნოლოგიისა და ნეოანტიგენების აღმოჩენის შესახებ მზარდმა ცოდნამ გააუმჯობესა ვაქცინის დიზაინი, ხოლო ადიუვანტების, იმუნური ინჰიბიტორების და კომბინირებული რეჟიმების ჩართვამ პრეკლინიკურ და კლინიკურ კვლევებში აჩვენა სინერგიული ეფექტიანობა. ფარმაკოლოგიურად, ახალი ვაქცინები მოქმედებენ ანტიგენების მოქმდების გაძლიერებით, ციტოტოქსიკური T-ლიმფოციტების სტიმულირებით და სიმსივნური მიკრო გარემოს მოდულირებით იმუნოსუპრესიის დასაძლევად. ნანოპარტიკულური მიწოდების სისტემები ასევე აუმჯობესებენ სტაბილურობას, ბიოდისტრიბუციას და იმუნოგენური კომპონენტების მიზნობრივ მიწოდებას, რაც ზრდის ვაქცინის სიძლიერეს. კლინიკურად, კიბოს ვაქცინები შეფასების პროცესშია მელანომის, ფილტვის, სარძევე ჯირკვლის, პროსტატის და ჰემატოლოგიური სიმსივნეების შემთხვევაში, მიუხედავად იმედისმომცემი შედეგებისა, გამოწვევები რჩება, მათ შორის სიმსივნის ჰეტეროგენურობა, იმუნური აცილების მექანიზმები და პაციენტის რეაქციის სხვადასხვაობა, რაც ხაზს უსვამს ბიომარკერების მნიშვნელობას პაციენტის სტრატიფიკაციისა და მკურნალობის

მონიტორინგისთვის. მომავალში ყურადღება გამახვილდება უფრო პერსონალიზებულ ვაქცინებზე, რომლებიც განსაზღვრული იქნება მომდევნო თაობის რიგითობით, ხელოვნური ინტელექტის საფუძველზე ანტიგენის პროგნოზირებით და სხვა იმუნოთერაპიული მიდგომების ინტეგრაციით, როგორიცაა CAR-T უჯრედების თერაპია და ონკოლიტური ვირუსები. პერსონალიზებული მედიცინისა და კიბოს იმუნოლოგიის კონვერგენცია იძლევა იმის მოლოდინს, რომ კიბოს საწინააღმდეგო ვაქცინები შესაძლოა გახდნენ კომპლექსური ონკოლოგიური მკურნალობის ქვაკუთხედი. სამეცნიერო დისკურსის გაგრძელება მნიშვნელოვანია ამ სტრატეგიების დახვეწის, რეგულაციური და წარმოებითი ბარიერების გადალახვისა და ხელმისაწვდომობის უზრუნველყოფისთვის. ეს ინოვაციები ერთობლივად, ხაზს უსვამენ ანტიკარცინომური ვაქცინების გარდამტეხ პოტენციალს კიბოს პრევენციის, მკურნალობისა და პაციენტების გადარჩენის მომავლის ფორმირებაში.

საკვანძო სიტყვები: *სიმსივნის საწინააღმდეგო ვაქცინები; კიბოს იმუნოთერაპია; სიმსივნის მიკროგარემო; პერსონალიზებული მედიცინა; mRNA ვაქცინები; დენდრიტული უჯრედების ვაქცინები; იმუნური საკონტროლო პუნქტების ინჰიბიტორები; ფარმაკოლოგია; კლინიკური გამოყენება.*

SCIENTIFIC DISCOURSE ON THE CHARACTERISTICS OF NEW ANTICANCER VACCINES: INNOVATIONS, PHARMACOLOGY, CLINICAL APPLICATIONS AND FUTURE PERSPECTIVES

Nodar Sulashvili

MD, PhD, Doctor of Pharmaceutical and Pharmacological Sciences in Medicine, Associate Affiliated Professor of Pharmacology, Clinical Pharmacy and Pharmacotherapy Direction at Shota Meskhia Zugdidi State University, Head of The Pharmacy Bachelor Education Study Program at Shota Meskhia Zugdidi State University, Zugdidi, Georgia; Invited Lecturer (Invited Professor) of Scientific Research-Skills Center at Tbilisi State Medical University; Invited Lecturer of Clinical Pharmacology Department at Tbilisi State Medical University; Tbilisi, Georgia; Scientific Researcher and Invited Professor of Department of Pharmaceutical Management at Yerevan State Medical University After Mkhitar Heratsi, Yerevan, Armenia.

ORCID **0000-0002-9005-8577;**

E-mail: n.sulashvili@ug.edu.ge

Nato Alavidze

MD, PhD, Doctor of Pharmaceutical Sciences, Professor of Akaki Tsereteli State University, Faculty of Medicine, Department of Pharmacy, Kutaisi, Georgia; Professor, Head of the Pharmacy Education Study Program at Shota Meskhia Zugdidi State University; Professor, Dean Faculty of Medicine at East European University, Tbilisi, Georgia.

ORCID 0000-0001-6695-5924

Marika Sulashvili

MD, Doctor of Family Medicine, Invited Lecturer of Tbilisi State Medical University, Department of Molecular and Medical Genetics, Invited Professor of Biochemistry and Molecular and Medical Genetics at The University of Georgia; Tbilisi, Georgia.

Corresponding Author: Dr. Professor Nodar Sulashvili

Mail: n.sulashvili@ug.edu.ge

Mob: +995-597-12-17-28

SCIENTIFIC DISCOURSE ON THE CHARACTERISTICS OF NEW ANTICANCER VACCINES: INNOVATIONS, PHARMACOLOGY, CLINICAL APPLICATIONS AND FUTURE PERSPECTIVES

ABSTRACT

The development of new anticancer vaccines represents one of the most promising innovations in oncology, integrating advances in immunology, molecular biology, nanotechnology, pharmacy, pharmacology and personalized medicine. Unlike conventional chemotherapeutic and radiotherapeutic strategies, anticancer vaccines aim to harness and amplify the body's own immune system to recognize, target, and eliminate malignant cells while minimizing off-target toxicities. Recent innovations include peptide- and protein-based vaccines, dendritic cell–based formulations, viral vector platforms, and mRNA vaccines, which offer high versatility and potential for rapid adaptation to individual tumor antigens. A growing understanding of tumor immunology and neoantigen discovery has enhanced vaccine design, while the incorporation of adjuvants, immune checkpoint inhibitors, and combination regimens has demonstrated synergistic efficacy in preclinical and clinical trials. Pharmacologically, new vaccines function by enhancing antigen presentation, stimulating cytotoxic T lymphocytes, and modulating the tumor microenvironment to overcome immunosuppression. Nanoparticle delivery systems further improve stability, biodistribution, and targeted delivery of immunogenic components, enhancing vaccine potency.

Clinically, cancer vaccines are being evaluated in melanoma, lung, breast, prostate, and hematologic malignancies. Despite encouraging outcomes, challenges remain, including tumor heterogeneity, immune evasion mechanisms, and variability in patient response, highlighting the importance of biomarkers for patient stratification and treatment monitoring. Future perspectives point toward increasingly personalized vaccines guided by next-generation sequencing, artificial intelligence–based antigen prediction, and integration with other immunotherapeutic modalities such as CAR-T cell therapy and oncolytic viruses. The convergence of precision medicine and cancer immunology suggests that anticancer vaccines may evolve into a cornerstone of comprehensive oncology care. A continued scientific discourse is essential to refine these strategies, address regulatory and manufacturing barriers, and ensure accessibility. Collectively, these innovations underscore the transformative potential of anticancer vaccines in shaping the future landscape of cancer prevention, treatment, and survivorship of patients.

Keywords: *Anticancer vaccines; Cancer immunotherapy; Tumor microenvironment; Personalized medicine; mRNA vaccines; Dendritic cell vaccines; Immune checkpoint inhibitors; Pharmacology; Clinical applications.*

INTRODUCTION

The field of oncology has undergone remarkable transformation over the past several decades, evolving from an era dominated by surgery, radiotherapy, and chemotherapy into a new paradigm defined by molecular medicine, targeted therapy, and immuno-oncology. Among the most promising innovations reshaping this therapeutic landscape is the development of anticancer vaccines (Tanyi, J. L., Bobisse, S., Ophir, E., Tuyaerts, S., and et al (2018). These vaccines represent a significant milestone in translational medicine, as they are designed to mobilize the body's own immune system to selectively recognize and destroy malignant cells while sparing normal tissues. The concept of harnessing the immune system to combat cancer is not new, yet only in recent years have technological advances in molecular biology, immunology, bioinformatics, and nanotechnology enabled the design of vaccines that can overcome the barriers previously limiting their success (Blass, E., & Ott, P. A. (2021).

Cancer continues to be one of the leading causes of morbidity and mortality worldwide, responsible for nearly ten million deaths annually according to the most recent global estimates. Despite advances in screening, early detection, and therapeutic interventions, many cancers remain refractory to treatment, recur after initial remission, or develop resistance to conventional therapies.

Chemotherapy, although effective against rapidly dividing cells, is associated with severe toxicity, immunosuppression, and off-target damage to healthy tissues. Targeted therapies, while more selective, are often undermined by the emergence of resistance mutations and the complexity of tumor heterogeneity. Immunotherapy, and within it the development of anticancer vaccines, provides an avenue for long-term disease control and potentially curative outcomes by engaging adaptive immune mechanisms capable of generating durable memory responses (Hu, Z., Leet, D. E., Allesøe, R. L., Oliveira, G., and et al 2021).

The theoretical foundation of anticancer vaccines rests on the identification of tumor-associated antigens (TAAs) and tumor-specific antigens (TSAs) that can serve as immunogenic targets. The immune system is naturally capable of distinguishing between self and non-self, but tumors frequently evolve mechanisms of immune evasion such as antigen loss, downregulation of major histocompatibility complex (MHC) molecules, or recruitment of immunosuppressive regulatory cells within the tumor microenvironment. Cancer vaccines aim to break this tolerance by re-presenting relevant tumor antigens in a context that stimulates effective immune recognition. This is accomplished through diverse strategies, including peptide-based vaccines that use short antigen fragments, protein-based vaccines presenting larger immunogenic sequences, dendritic cell vaccines that serve as professional antigen-presenting cells, DNA and RNA vaccines encoding tumor antigens, and viral or bacterial vectors engineered to deliver tumor-specific sequences. Each platform carries unique advantages and challenges in terms of immunogenicity, safety, scalability, and clinical applicability (Sahin, U., & Türeci, Ö. 2018).

The history of cancer vaccines can be traced back to the pioneering work of William Coley in the late nineteenth century, when bacterial extracts were used in an attempt to stimulate antitumor immune responses. Although crude and poorly understood at the time, Coley's "toxins" laid the foundation for the idea that immune stimulation could induce tumor regression. In the modern era, breakthroughs in molecular immunology have enabled a much more precise and rational design of vaccines. The approval of sipuleucel-T, a dendritic cell–based vaccine for prostate cancer, provided the first proof-of-concept that therapeutic vaccines can achieve regulatory approval and clinical benefit. Since then, the field has expanded significantly, with multiple experimental vaccines advancing through early- and late-phase clinical trials in a variety of malignancies, including melanoma, lung cancer, breast cancer, glioblastoma, and hematological cancers (Lorentzen, C. L., Haanen, J. B., Met, Ö., & Svane, I. M. 2022).

One of the major innovations driving this progress has been the development of mRNA vaccine platforms, whose flexibility, rapid production capability, and demonstrated success in

infectious diseases such as COVID-19 have accelerated their translation into oncology. mRNA vaccines can encode multiple tumor antigens simultaneously, allowing for personalized vaccine design based on individual patient tumor mutational profiles. This aligns with the broader trend of precision oncology, in which treatment is tailored to the genetic and immunologic features of each patient's tumor. Moreover, the integration of artificial intelligence and next-generation sequencing technologies has enhanced the ability to predict immunogenic neoantigens, further refining vaccine design and increasing the likelihood of therapeutic efficacy (Ott, P. A., Hu-Lieskovan, S., Chmielowski, B., Govindan, R., Naing, A., and et al 2020).

Pharmacologically, anticancer vaccines exert their effects by enhancing antigen processing and presentation, stimulating cytotoxic CD8+ T lymphocytes capable of killing tumor cells, and modulating the tumor microenvironment to favor immune activation over suppression. Vaccine-induced immune responses can be augmented through the co-administration of adjuvants such as Toll-like receptor agonists, cytokines, or nanoparticles that improve antigen delivery and immune recognition. Importantly, the advent of immune checkpoint inhibitors targeting PD-1, PD-L1, and CTLA-4 pathways has created opportunities for synergistic combinations. By releasing the brakes on T-cell activity, checkpoint inhibitors enhance the immune responses initiated by vaccines, increasing their clinical impact. This combinatorial approach has already shown promise in preclinical models and early-phase clinical studies (Hilf, N., Kuttruff-Coqui, S., Frenzel, K., Bukur, V., and et al 2019).

Despite these encouraging developments, significant challenges remain. Tumor heterogeneity poses a major barrier, as cancers within the same patient or across different patients may express distinct antigenic profiles, making the identification of universally effective targets difficult. Additionally, tumors employ immune evasion strategies such as the recruitment of myeloid-derived suppressor cells, regulatory T cells, and the secretion of immunosuppressive cytokines, which limit the efficacy of vaccine-induced responses. Another obstacle lies in the variability of patient immune competence, as elderly or immunocompromised individuals may not mount robust responses to vaccination. Manufacturing complexities, regulatory hurdles, and the cost of developing highly personalized vaccines also present real-world barriers to widespread clinical adoption (Melero, I., Gaudernack, G., Gerritsen, W., Huber, C., and et al 2014).

Nevertheless, the future of anticancer vaccines appears increasingly promising. Ongoing research is exploring the integration of vaccines with multimodal therapies, including radiotherapy, oncolytic viruses, and adoptive cell transfer strategies such as chimeric antigen receptor (CAR) T cells. These combinations hold the potential to amplify immune responses, increase antigen release,

and overcome tumor-induced immunosuppression. The field is also moving toward preventive oncology, where vaccines may be developed to target high-risk individuals with precancerous lesions or genetic predispositions, thereby intercepting malignancy before it develops. Advances in nanotechnology offer new methods for antigen delivery, increasing stability, targeted biodistribution, and controlled release of vaccine components. At the same time, global collaborations, expanded clinical trials, and regulatory innovations will be necessary to translate these laboratory breakthroughs into accessible treatments for diverse patient populations (Palucka, K., & Banchereau, J. 2023).

Ultimately, anticancer vaccines represent not only a therapeutic strategy but also a paradigm shift in the way cancer is conceptualized and treated. Instead of relying solely on cytotoxic interventions, vaccines embody the principle of harnessing endogenous immune mechanisms to achieve long-lasting tumor control and immunological memory. This approach has the potential to transform cancer into a manageable or even preventable disease, altering its trajectory as a global health burden. As scientific discourse continues to expand, encompassing innovations in pharmacology, clinical applications, and forward-looking strategies, anticancer vaccines stand poised at the intersection of immunology, biotechnology, and precision medicine. They embody the next frontier in oncology, one in which science, technology, and patient-centered care converge to create a future of improved survival, reduced toxicity, and enhanced quality of life for individuals affected by cancer (Saxena, M., van der Burg, S. H., Melief, C. J. M., & Bhardwaj, N. 2021).

GOAL

The primary goal of this scientific discourse is to provide a comprehensive analysis of the emerging field of anticancer vaccines, with a particular focus on their innovative design strategies, pharmacological mechanisms, clinical applications, and prospective role in oncology. By synthesizing current evidence from preclinical and clinical research, the aim is to highlight how advances in tumor immunology, molecular biology, nanotechnology, and personalized medicine are converging to shape the development of effective cancer vaccines. The discourse seeks to critically evaluate both the successes and limitations of existing vaccine platforms, assess their integration with other immunotherapeutic modalities such as checkpoint inhibitors and cellular therapies, and identify the major barriers that must be overcome for broader clinical implementation. This work aims to frame anticancer vaccines not merely as experimental interventions but as a transformative therapeutic and potentially preventive strategy with the capacity to alter the trajectory of cancer treatment worldwide. Through detailed exploration of pharmacological properties, immunological

pathways, and patient-centered applications, the ultimate goal is to stimulate scientific dialogue, encourage innovative research, and support the translation of laboratory breakthroughs into accessible, safe, and effective clinical tools. In doing so, the study aspires to contribute to a deeper understanding of how anticancer vaccines can become an integral component of precision oncology and global cancer control in the future.

METHODOLOGY

This scientific discourse was conducted through a comprehensive literature-based approach, integrating primary research articles, systematic reviews, meta-analyses, clinical trial reports, and authoritative sources from international databases and peer-reviewed journals. The methodology was designed to capture the multidimensional aspects of anticancer vaccines, including their molecular innovations, pharmacological properties, immunological mechanisms, clinical applications, and future directions in oncology. Relevant publications were identified using advanced search strategies in databases such as PubMed, Scopus, Web of Science, MEDLINE, and Embase, employing keywords including “anticancer vaccines,” “cancer immunotherapy,” “tumor immunology,” “mRNA vaccines,” “dendritic cell vaccines,” “immune checkpoint inhibitors,” “clinical trials,” and “personalized oncology.” The search was restricted to publications in English, covering studies from the early 2010s to the present, ensuring that the most recent technological and clinical advances were included.

A multi-stage selection process was employed to ensure the inclusion of high-quality and relevant studies. Initially, titles and abstracts were screened to identify studies addressing innovations in vaccine platforms, immunological mechanisms, or clinical outcomes. Subsequently, full-text articles were reviewed for detailed evaluation of vaccine types, pharmacological mechanisms, immunogenicity, efficacy, safety profiles, and translational potential. Both preclinical and clinical studies were considered, encompassing in vitro experiments, animal models, phase I–III clinical trials, and post-marketing evaluations where available. Studies reporting on combination therapies, including the use of vaccines with immune checkpoint inhibitors, cellular therapies, or nanotechnology-based delivery systems, were given particular attention due to their growing relevance in contemporary oncology.

Data extraction focused on multiple dimensions, including vaccine platform type, antigen selection and delivery strategies, adjuvant use, pharmacodynamic and pharmacokinetic properties, immune response markers, clinical endpoints, adverse effects, and observed therapeutic outcomes. Trends and patterns were synthesized to provide a coherent understanding of current achievements,

limitations, and emerging directions in anticancer vaccine development. This methodology enabled a holistic analysis that combines mechanistic, pharmacological, and clinical perspectives, supporting an integrative discussion on the potential of anticancer vaccines to transform cancer prevention and treatment. By systematically consolidating existing evidence and highlighting gaps in knowledge, this discourse provides a foundation for future research and informed clinical decision-making in the evolving field of cancer immunotherapy.

RESULTS AND DISCUSSION

The relentless pursuit of effective and tolerable cancer therapies has ushered in a new epoch dominated by immunotherapy, with anticancer vaccines standing as one of its most sophisticated and promising vanguard. Unlike traditional prophylactic vaccines, these therapeutic agents are designed to harness the body's own immune system, educating and empowering it to recognize and eradicate established malignant cells. The results emerging from decades of research and recent clinical trials paint a complex yet profoundly optimistic picture, revealing a field in rapid transition from theoretical promise to tangible clinical reality. The discourse surrounding these vaccines encompasses a intricate tapestry of innovations in antigen selection and delivery platforms, a nuanced and evolving understanding of their pharmacological behavior, a growing body of evidence from clinical applications across a spectrum of malignancies, and a forward-looking perspective that anticipates the challenges and opportunities that lie ahead. This discussion synthesizes these multifaceted results, weaving together the threads of scientific discovery to present a comprehensive overview of the current state and future trajectory of anticancer vaccines.

The foundational principle of anticancer vaccination is the specific activation of the host immune system against tumor-associated antigens (TAAs) or tumor-specific antigens (TSAs). The results of extensive genomic and proteomic research have been instrumental in identifying a vast repertoire of potential targets. The distinction between TSAs, such as neoantigens derived from somatic mutations unique to each patient's tumor, and shared TAAs, which are overexpressed in tumors but present in some normal tissues, is a critical determinant of vaccine efficacy and safety. The empirical data convincingly demonstrate that vaccines targeting neoantigens hold a significant advantage. Because these epitopes are entirely foreign to the immune system and not subject to central tolerance, they can elicit potent, high-affinity T-cell responses with a markedly reduced risk of autoimmunity. The results from pioneering studies utilizing next-generation sequencing and bioinformatic prediction algorithms have shown that the mutational burden of a tumor, and consequently its neoantigen landscape, varies dramatically across cancer types. Cancers with high

mutational burden, such as melanoma, non-small cell lung cancer, and carcinomas with microsatellite instability, present the most fertile ground for neoantigen vaccine development. The successful identification and prioritization of immunogenic neoantigens represent a monumental achievement, transforming a once insurmountable challenge into a feasible, albeit complex, personalized medicine workflow.

Parallel to the revolution in antigen discovery are the innovations in vaccine delivery platforms, each with distinct pharmacological profiles and mechanisms of immune activation. The results from comparative preclinical and clinical studies indicate that no single platform is universally superior; rather, the choice of platform is dictated by the nature of the antigen, the desired immune response, and practical considerations of manufacturing and deployment. Viral vector vaccines, employing engineered viruses like adenovirus or poxvirus, have yielded robust results due to their inherent ability to infect antigen-presenting cells (APCs) and provoke strong innate immune reactions through pathogen-associated molecular patterns. This intrinsic adjuvant effect promotes potent T-cell priming. However, pharmacological studies have also highlighted the limitations of this approach, primarily the development of neutralizing antibodies against the viral vector itself, which can impede repeated administration and reduce efficacy upon booster shots. This has led to strategies such as prime-boost regimens using different vectors to circumvent pre-existing immunity (Yarchoan, M., Johnson, B. A., Lutz, E. R., Laheru, D. A., & Jaffee, E. M. 2022).

The results concerning nucleic acid vaccines, specifically mRNA vaccines, have catapulted this platform to the forefront following its validation during the COVID-19 pandemic. The pharmacological advantages of mRNA are multifaceted. Firstly, its mechanism of action is entirely within the cytoplasm of host cells, eliminating any risk of genomic integration. Secondly, the rapid in vitro transcription production process is highly scalable and amenable to personalization, a crucial factor for neoantigen vaccines. The critical pharmacological breakthrough for mRNA vaccines was the development of sophisticated delivery systems, primarily lipid nanoparticles (LNPs). These LNPs protect the fragile mRNA from ubiquitous nucleases, facilitate cellular uptake, and, importantly, provide their own potent adjuvant effect by stimulating innate immune pathways. Results from numerous trials demonstrate that mRNA-LNP vaccines can induce strong and broad CD4+ and CD8+ T-cell responses against encoded neoantigens. The pharmacokinetics are transient, with protein expression typically lasting a few days, which is sufficient for immune priming but minimizes persistent antigen exposure that could lead to T-cell exhaustion. The dose-ranging studies

have been essential in finding the balance between immunogenicity and manageable reactogenicity, typically transient flu-like symptoms associated with innate immune activation (Sulashvili, N., Gorgaslidze, N., Gabunia, L., Alavidze, N., Sulashvili, M. 2024).

Peptide-based vaccines, administering minimal epitopes directly, represent a more defined approach. The results from clinical trials show that they are generally safe and well-tolerated. However, their pharmacology presents challenges. Short peptides can bind directly to MHC molecules on any nucleated cell, including non-professional APCs, leading to T-cell activation without proper co-stimulation and potential anergy. Furthermore, they are often poorly immunogenic alone, necessitating co-administration with potent adjuvants and delivery systems. The results have been more encouraging for long peptides, which require processing by professional APCs, ensuring a more robust and effective T-cell response. The choice of adjuvant is paramount; from traditional options like Montanide ISA to modern molecular agonists of Toll-like receptors (e.g., Poly-ICLC, CpG oligonucleotides), the adjuvant can dramatically alter the magnitude and quality of the immune response. Dendritic cell (DC) vaccines, the most personalized platform, involve isolating a patient's own DCs, loading them with tumor antigens ex vivo, and reinfusing them. The results of the seminal sipuleucel-T trial for prostate cancer proved the principle that an autologous cellular vaccine can confer a survival benefit. However, the complex, costly, and labor-intensive manufacturing process limits its widespread applicability. Pharmacologically, the fate and functionality of these reinfused DCs in the immunosuppressive tumor microenvironment remain areas of active investigation (Sulashvili, N., Gorgaslidze, N., Gabunia, L., Alavidze, N., Sulashvili, M. 2024).

The evolving field of anticancer vaccines represents one of the most promising frontiers in modern oncology, combining advances in immunology, molecular biology, nanotechnology, and precision medicine. Recent years have seen substantial progress in vaccine platforms, mechanisms of action, and clinical applications, highlighting the capacity of these therapies to induce targeted antitumor immune responses while minimizing off-target toxicity. Peptide-based vaccines utilize short amino acid sequences corresponding to tumor-associated antigens and have demonstrated the ability to stimulate cytotoxic T lymphocyte responses. These vaccines offer specificity and relative ease of production, though immunogenicity can be limited by HLA restriction and the need for adjuvants or delivery systems. Protein-based vaccines present larger immunogenic

sequences, offering multiple epitopes for T-cell recognition and broader immune activation, but face challenges in stability, degradation, and the requirement for carrier systems. Dendritic cell vaccines represent a more personalized approach, wherein autologous or allogeneic dendritic cells are pulsed with tumor antigens to stimulate potent immune responses. Sipuleucel-T, approved for metastatic prostate cancer, exemplifies the clinical feasibility of this approach. Viral vector vaccines leverage attenuated viruses to deliver tumor antigen-encoding sequences, utilizing inherent immunostimulatory properties, although they must be engineered to minimize pathogenicity and pre-existing antiviral immunity (Sulashvili, N., Gorgaslidze, N., Gabunia, L., Alavidze, N., Sulashvili, M. 2024). DNA and RNA vaccines, particularly mRNA-based formulations, have emerged as highly versatile tools capable of rapid production, multi-antigen encoding, and potent T-cell activation. The success of mRNA vaccines in infectious disease applications has accelerated their translation into oncology, with early-phase trials demonstrating robust immunogenicity, safety, and adaptability for personalized therapy (Lorentzen, C. L., Haanen, J. B., Met, Ö., & Svane, I. M. (2022).

Mechanistically, anticancer vaccines prime and expand antigen-specific T lymphocytes capable of recognizing and eliminating tumor cells. Effective vaccines promote antigen uptake by antigen-presenting cells, processing, and presentation via major histocompatibility complex molecules, followed by activation of helper and cytotoxic T cells. Cytotoxic T lymphocytes exert antitumor activity through perforin and granzyme release, apoptosis induction, and production of pro-inflammatory cytokines such as interferon-gamma. Vaccines also modulate the tumor microenvironment by enhancing dendritic cell maturation, reducing regulatory immune cells, and promoting chemokine-mediated T-cell infiltration. Nanotechnology-based delivery systems, including lipid nanoparticles, polymeric carriers, and liposomes, augment vaccine potency by protecting antigens, improving biodistribution, and enabling controlled release. Immunostimulatory adjuvants, such as Toll-like receptor agonists, cytokines, or saponin derivatives, further amplify dendritic cell activation and T-cell priming, overcoming baseline immune tolerance.

Clinical applications of anticancer vaccines span a variety of malignancies, reflecting the diversity of tumor antigen targets and vaccine platforms. In melanoma, peptide and dendritic cell vaccines targeting gp100, MART-1, and NY-ESO-1 have induced measurable immune responses and modest improvements in progression-free survival, particularly in combination with checkpoint

inhibitors. Lung cancer, including non-small cell and small cell subtypes, has been targeted using MUC1, WT1, and EGFR-derived peptides, with early-phase trials reporting immune activation and evidence of tumor regression in selected patients. Breast cancer studies have explored HER2/neu-targeted vaccines, eliciting humoral and cellular immunity with favorable safety profiles, though efficacy remains modest in advanced stages. Hematologic malignancies, such as acute myeloid leukemia, have been addressed using WT1-targeted peptide vaccines and dendritic cell–based approaches, demonstrating tumor-specific T-cell responses and minimal toxicity. Glioblastoma, due to its immunosuppressive microenvironment, has been targeted with multipeptide vaccines and personalized neoantigen vaccines, showing encouraging immunogenicity and early signs of improved survival in phase I and II trials.

Anticancer vaccines generally exhibit favorable safety profiles, particularly compared to cytotoxic therapies. Reported adverse events are often mild to moderate, including injection site reactions, flu-like symptoms, fatigue, and low-grade fever. Severe immune-related adverse events are rare but have occurred, especially in combination regimens with checkpoint inhibitors. Long-term consequences, response durability, and potential autoimmune reactions remain under investigation, highlighting the importance of longitudinal monitoring and biomarker-driven patient selection. Vaccine efficacy varies according to tumor type, platform, antigen selection, and patient-specific factors, emphasizing the need for personalized approaches.

Combination strategies with other immunotherapeutic modalities enhance vaccine efficacy. Immune checkpoint inhibitors targeting PD-1, PD-L1, and CTLA-4 synergize with vaccine-induced T-cell activation by preventing tumor-mediated T-cell exhaustion. Adoptive cell therapies, including CAR-T cells and tumor-infiltrating lymphocyte expansions, benefit from vaccines that prime antigen-specific immune responses. Oncolytic viruses selectively lysing tumor cells can increase antigen release and stimulate local immune responses, complementing vaccine therapy. These integrative approaches highlight the necessity of multimodal strategies to overcome systemic and local barriers to effective antitumor immunity.

Challenges in anticancer vaccine development include tumor heterogeneity, immune evasion, patient variability, and manufacturing complexity. Heterogeneity complicates antigen selection and contributes to variable responses. Tumors evade immune surveillance via immunosuppressive cytokines, regulatory T cells, and MHC downregulation. Patient factors such as age, immune competence, prior therapies, and comorbidities influence immune responses, necessitating individualized design. Manufacturing personalized vaccines remains costly and

complex, and standardization of endpoints, immune monitoring, and clinical efficacy criteria is essential for regulatory approval and cross-study comparisons.

Anticancer vaccines exemplify the convergence of immunology, pharmacology, and precision medicine, offering targeted, durable, and minimally toxic cancer therapy. Early clinical results are encouraging, but ongoing research must address limitations posed by tumor heterogeneity, immune suppression, and patient variability. Collaborative efforts spanning basic science, translational research, and clinical trials are essential to accelerate development and integration into comprehensive oncology care. As vaccine platforms evolve, their combination with other immunotherapies, adoption of personalized approaches, and preventive applications are likely to redefine cancer treatment. The continuous evolution of anticancer vaccines underscores the importance of scientific discourse that evaluates mechanistic insights, clinical outcomes, safety profiles, and translational potential, ultimately transforming immune-based therapies into cornerstone strategies for improved survival, enhanced quality of life, and reduced global cancer burden (Yarchoan, M., Johnson, B. A., Lutz, E. R., Laheru, D. A., & Jaffee, E. M. 2022).

The translation of these pharmacological innovations into clinical benefit is evidenced by a growing body of results from clinical trials across diverse oncological indications. In melanoma, a cancer historically responsive to immunotherapy, the results have been particularly striking. Trials investigating personalized neoantigen vaccines, using both mRNA and peptide platforms, have consistently demonstrated the induction of polyfunctional, neoantigen-specific T-cell responses. Importantly, these vaccine-induced T cells have been shown to traffic to tumor sites and can evolve into memory populations, suggesting the potential for long-term disease control. In several studies, the combination of neoantigen vaccination with immune checkpoint inhibitors (ICIs) like anti-PD-1 antibodies has yielded synergistic results. The vaccine acts to expand the repertoire and quantity of tumor-specific T cells, while the ICI removes the inhibitory signals that these T cells encounter within the tumor, effectively releasing the brakes on a more powerful army. Results have shown higher response rates and deeper tumor regressions with the combination than would be expected with either modality alone in treatment-naïve or ICI-refractory settings.

In glioblastoma (GBM), a tumor with a notoriously immunosuppressive and "cold" microenvironment, the clinical challenge is immense. Yet, vaccine strategies have shown glimmers of promise. Results from trials targeting cytomegalovirus antigens or patient-specific neoantigens have indicated a potential survival benefit in a subset of patients. Immunological analyses often confirm successful priming of antigen-specific responses in the periphery. However, a critical discussion point is the frequent disconnect between peripheral immune activation and clinical

efficacy in GBM. This highlights a fundamental pharmacological and biological barrier: the blood-brain barrier and the unique immunosuppressive mechanisms within the central nervous system that can sequester the tumor from vaccine-induced immunity. These results underscore that vaccine efficacy is not solely a function of generating a response but is equally dependent on enabling that response to effectively reach and function within the tumor bed.

In the realm of viral oncology, the results have been more straightforwardly positive. Therapeutic vaccines against human papillomavirus (HPV)-related cancers, targeting oncoproteins E6 and E7, have shown significant clinical activity in pre-cancerous lesions like cervical intraepithelial neoplasia. The results reinforce the concept that targeting a truly foreign, viral antigen in a non-advanced, minimally immunosuppressed setting is a highly effective strategy. For prostate cancer, the DC vaccine sipileucel-T remains a landmark achievement. Its pivotal trial results showed a significant improvement in overall survival, leading to its regulatory approval. This success, despite a lack of objective tumor response rates by traditional radiological criteria, sparked an important discussion about the mechanism of action of cancer vaccines. It suggested that the benefit may be mediated by a slower modification of the disease course rather than rapid tumor destruction, necessitating new endpoints for future trials, such as overall survival rather than progression-free survival.

The discussion of clinical results would be incomplete without addressing the significant challenges that have emerged. A recurring theme across many trials is the modest objective response rates when vaccines are used as monotherapy, particularly in advanced, heavily pre-treated disease. The results point to several contributing factors. Firstly, the tumor microenvironment (TME) is often a formidable fortress of immunosuppression, replete with regulatory T cells, myeloid-derived suppressor cells, M2 macrophages, and inhibitory cytokines. A vaccine may successfully generate effector T cells, but these cells can become functionally impaired or "exhausted" upon entering the TME. Secondly, tumors employ immune evasion strategies, such as downregulation of MHC molecules, making them invisible to T cells, even if those T cells are present and functional. This phenomenon, known as antigen loss variance, is a common escape mechanism observed in patients who initially respond to vaccine therapy but later relapse. Results from biopsies post-relapse often reveal tumor cells that no longer express the targeted neoantigen. Furthermore, the heterogeneity within a tumor means that not all cells may express the chosen antigen, allowing for the outgrowth of antigen-negative clones under the selective pressure of the vaccine-induced immune response.

These challenges have steered the field towards rational combination strategies, the results of which are defining the future of cancer vaccinology. The combination with immune checkpoint

blockade is the most clinically advanced and validated. The pharmacological rationale is robust: vaccines expand T-cell clones, ICIs enhance their functionality. Results from multiple trials confirm this synergy. Other combination partners showing promising results include cytokines like IL-2 or IL-15 to support T-cell expansion and survival, agonists of co-stimulatory receptors (e.g., OX40, 4-1BB) to provide positive signals, and therapies targeting the immunosuppressive components of the TME, such as inhibitors of IDO or TGF-β. Perhaps the most transformative combination is with cytoreductive therapies like chemotherapy or radiotherapy. Once thought to be immunosuppressive, it is now clear that these modalities can paradoxically enhance vaccine responses. Results demonstrate that chemotherapy can cause immunogenic cell death, releasing a wave of additional TAAs and DAMPs that act as an in situ adjuvant, licensing APCs and broadening the immune response beyond the vaccine-targeted antigens (a phenomenon known as epitope spreading). Radiotherapy can similarly modify the TME, increasing vascular permeability and T-cell infiltration, effectively turning a "cold" tumor "hot." The timing and sequencing of these combinations are critical pharmacological variables under intense investigation.

Looking towards the future, the perspective for anticancer vaccines is both exciting and demanding. The direction is unequivocally towards greater personalization. The results to date make a compelling case that neoantigen-directed vaccines represent the path of greatest potential. The future will see the refinement and acceleration of the neoantigen pipeline—from rapid tumor sequencing and bioinformatic prediction of high-affinity epitopes to automated, GMP-compliant manufacturing of bespoke vaccines within a clinically relevant timeframe. The goal is to shift this modality from a research-intensive endeavor to a standardized clinical service. Furthermore, the next generation of vaccines will likely move beyond simple peptides or mRNA encoding single antigens. Results from preclinical models suggest that vaccines encoding entire tumor rejection antigens or personalized sets of neoantigens fused into novel polyepitope strings can elicit broader and more effective responses. The development of off-the-shelf vaccines targeting shared public neoantigens, common mutations found in certain cancer subtypes in many patients, offers a more practical alternative to fully personalized approaches for some indications.

Future research emphasizes personalization, optimized delivery systems, and integration with advanced immunotherapies. Neoantigen-based vaccines, guided by next-generation sequencing and computational prediction algorithms, target patient-specific mutations with high immunogenicity. Artificial intelligence and machine learning refine antigen selection, predict immunogenicity, and anticipate adverse effects. Nanoparticle carriers, biodegradable polymers, and novel adjuvants enhance stability, targeted delivery, and controlled antigen release. Preventive

vaccines for high-risk individuals, including those with genetic predispositions or premalignant lesions, represent an emerging frontier. Insights into tumor microenvironment dynamics and microbiome interactions may further improve vaccine efficacy and durability.

Another future perspective lies in enhancing vaccine pharmacology through advanced biomaterial engineering. Results from innovative research indicate that scaffolds and implants can serve as synthetic immune niches. These devices can be designed to co-deliver antigens, adjuvants, and cytokines in a sustained release manner, locally recruiting and programming APCs in a controlled fashion over days or weeks, potentially obviating the need for multiple injections. This approach aims to mimic the natural kinetics of a lymph node, providing a more physiological and potent priming environment. Similarly, the direct targeting of antigens to specific receptors on APCs using antibody-based conjugates is a promising strategy to increase the efficiency of antigen uptake and presentation, thereby reducing the required vaccine dose and minimizing off-target effects.

The future clinical application of vaccines will also expand beyond therapeutic intervention in established disease. Results from minimal residual disease settings, following surgery or chemotherapy, suggest that this is an ideal scenario for vaccination. The tumor burden is low, the immunosuppressive network is less established, and the goal of eliminating lingering, dormant cells to prevent recurrence aligns perfectly with the mechanism of action of vaccines, which is to establish a long-lived, vigilant immune memory. In this adjuvant setting, vaccines could fundamentally change the natural history of cancer, transforming it from a lethal disease into a chronic condition controlled by the immune system. The ultimate future perspective may even include prophylactic vaccination for high-risk individuals, such as those with hereditary cancer syndromes. Vaccinating against key driver neoantigens before a tumor develops could enable immune surveillance to destroy pre-malignant cells as they arise, a truly transformative approach to cancer prevention (Sulashvili, N., Abzianidze, E., Chichoyan, N., Zarnadze, Sh. 2025).

Furthermore, the investigation into various vaccine platforms yields the conclusion that there is no single universal delivery system optimal for all scenarios. Each platform—viral vectors, nucleic acids, peptides, and dendritic cells—carries distinct pharmacological advantages and limitations. Viral vectors offer strong immunogenicity but face challenges from pre-existing immunity. Peptide vaccines are precise but often require complex adjuvants to overcome weak immunogenicity. Dendritic cell vaccines are profoundly personalized but logistically burdensome. The emergence of mRNA vaccines, particularly those encapsulated in lipid nanoparticles, represents a watershed moment, combining rapid development, scalability, inherent adjuvant properties, and

a favorable safety profile. This platform has demonstrated remarkable efficacy in inducing robust and multifaceted immune responses, positioning it as a leading modality for the future, especially for neoantigen applications. The collective experience with these platforms concludes that the choice of vector must be strategically aligned with the clinical context, target antigen, and desired immune outcome.

The analysis of clinical trial data leads to the sobering yet instructive conclusion that monotherapy with anticancer vaccines, particularly in advanced, metastatic settings with high tumor burden and profoundly immunosuppressive microenvironments, often yields modest objective response rates. This is not a failure of the concept but rather a reflection of the formidable biological barriers erected by established tumors. Vaccines can effectively prime and expand antigen-specific T-cell clones, but these effector cells are frequently rendered dysfunctional upon encountering the tumor microenvironment, which is replete with inhibitory cells, cytokines, and checkpoint pathways. This observation crucially concludes that the efficacy of a vaccine is not merely a function of its ability to induce an immune response in the periphery but is fundamentally dependent on the capacity of that response to infiltrate, function within, and overcome the immunosuppressive tumor niche.

The most significant remarks regarding clinical application: the future of anticancer vaccines lies overwhelmingly in rational combination therapies. The synergy observed with immune checkpoint inhibitors is particularly powerful and well-documented. The vaccine acts to expand the army of tumor-specific T cells, while checkpoint blockade removes the inhibitory signals that paralyze this army within the tumor. This combination has consistently been shown to enhance response rates and depth of response beyond what either agent can achieve alone. Similarly, combinations with conventional therapies like radiotherapy and certain chemotherapies are highly promising, as these modalities can modulate the tumor microenvironment, induce immunogenic cell death, and release additional antigens, thereby acting as in situ adjuvants that amplify the vaccine's effect. The conclusion is therefore that vaccines will increasingly be deployed as the initiating engine of an immune response within integrated, multimodal treatment regimens designed to simultaneously stimulate immunity and dismantle the barriers that suppress it (Keskin, D. B., Anandappa, A. J., Sun, J., Tirosh, I., and et al 2021).

The perspectives conclude that the most promising application of cancer vaccines may shift from the treatment of advanced, refractory disease to the adjuvant setting of minimal residual disease. Following curative-intent surgery or chemotherapy, the tumor burden is low, and the immunosuppressive network is less entrenched. In this scenario, the vaccine's capacity to establish

a potent, long-lasting immunological memory has the greatest potential to eradicate dormant tumor cells and prevent disease recurrence, effectively aiming to cure cancer by maintaining a state of perpetual surveillance. Furthermore, the prospective development of vaccines for cancer prevention in high-risk individuals, though a longer-term goal, represents the ultimate culmination of this therapeutic strategy, potentially intercepting carcinogenesis before it manifests clinically.

The scientific discourse conclusively affirms that anticancer vaccines have evolved from a promising hypothesis into a dynamic and essential component of modern oncology. They embody the principles of precision medicine and immunotherapy, offering a targeted, durable, and adaptable approach to cancer treatment. While challenges remain in optimizing their delivery, overcoming immune resistance, and integrating them effectively into clinical practice, the trajectory of progress is unequivocally positive. The lessons learned from past results have illuminated the path forward, guiding the development of next-generation vaccines and intelligent combination strategies. As research continues to unravel the complexities of tumor-immune interactions, anticancer vaccines are poised to play an increasingly central role in transforming cancer from a lethal disease into a controllable condition, ultimately fulfilling the promise of harnessing the body's own defenses to achieve long-term remission and cure.

The scientific discourse on anticancer vaccines reveals a field that has matured from a concept of elegant theory to a dynamic clinical discipline grounded in robust pharmacological principles and tangible, if sometimes complex, clinical results. The innovations in antigen identification, particularly the focus on neoantigens, and the diversification of delivery platforms have provided the necessary tools. The clinical results, while revealing the formidable challenges posed by established tumors, have unequivocally demonstrated the capacity of vaccines to induce tumor-specific immunity and, in the right contexts, confer clinical benefit. The future of the field does not lie in vaccines as standalone magic bullets but as intelligent and essential components of multimodal immunotherapy. Their role is to initiate, broaden, and diversify the anti-tumor immune response, which can then be sustained and amplified through strategic combinations with checkpoint inhibitors, modulators of the TME, and conventional therapies. The perspective is one of optimism, fueled by a deepening understanding of tumor immunology and continuous technological advancement. As the field moves towards more personalized, potent, and strategically deployed vaccines, the goal of harnessing the immune system as a definitive and durable weapon against cancer appears increasingly within reach. The ongoing scientific discourse will continue to be driven by rigorous clinical experimentation, thoughtful analysis of results, and an unwavering

commitment to translating immunological breakthroughs into prolonged and improved lives for patients.

THE FUTURE DEVELOPMENT AND CLINICAL IMPLEMENTATION OF ANTICANCER VACCINES

The future development and clinical implementation of anticancer vaccines must be pursued through a fully integrated, multidisciplinary framework that prioritizes the creation of synergistic treatment ecosystems over the development of isolated monotherapies.

This overarching directive can be broken down into five indispensable, interconnected pillars:

Establish a global collaborative infrastructure for neoantigen discovery and validation. This necessitates the creation of shared, standardized databases housing genomic, transcriptomic, and immunopeptidomic data from diverse patient populations. The objective is to move beyond bespoke, single-institution pipelines to a federated model where machine learning algorithms are trained on vast, diverse datasets. This will dramatically improve the predictive accuracy for immunogenic neoantigens, identify novel "public" neoantigens across ethnicities, and accelerate the selection of optimal targets for both personalized and "off-the-shelf" vaccine candidates, ensuring efficacy and broadening applicability.

Mandate the co-development of vaccines with complementary immunomodulators from the earliest preclinical stages. Research and development must abandon the siloed approach. Funding agencies and industry leaders should incentivize programs that intrinsically combine vaccine platforms with specific, rationally chosen partners—such as immune checkpoint inhibitors, cytokine therapies, TME modifiers, or targeted agents—based on a deep understanding of their synergistic pharmacology. Clinical trials must then be designed to optimize these combinations, rigorously testing sequencing, dosing, and scheduling to unlock maximal clinical benefit and overcome resistance mechanisms.

Pivot clinical trial focus decisively towards early-stage disease and minimal residual disease settings. The most impactful use of anticancer vaccines is likely to be as a consolidative therapy after initial cytoreduction (surgery, radiotherapy, chemotherapy). Regulatory and research priorities must shift to support large-scale, randomized trials in the adjuvant and neoadjuvant settings for high-risk cancers. The primary endpoint for these trials should be relapse-free survival, with the ultimate goal of achieving durable, curative immune memory. This strategic reorientation is paramount to demonstrating the true potential of vaccines to alter the natural history of cancer.

Revolutionize regulatory and manufacturing paradigms to accommodate personalized medicine. Regulatory agencies must collaboratively develop new, agile approval pathways that evaluate the entire *process* of personalization—from sequencing and bioinformatics to manufacturing—rather than solely the final product for each individual. Concurrently, massive investment is required in automating and decentralizing manufacturing. The goal is to create regional, GMP-compliant "biobanks" or manufacturing hubs capable of rapid, cost-effective production of patient-specific vaccines, turning a weeks-long complex procedure into a streamlined, accessible clinical service.

Cultivate a new generation of oncologists and a supportive clinical environment equipped for complex immunotherapy. Medical education and training must evolve to encompass the principles of cancer immunology and the unique management of immunotherapies. Hospital systems must build integrated molecular tumor boards that include immunologists, bioinformaticians, and cell therapists to guide patient selection and management. Preparing the healthcare ecosystem is as vital as developing the drug itself; without this, the successful integration of these advanced therapies will be hindered.

The final advice is to stop viewing anticancer vaccines as a standalone product and to start architecting a new **cancer immunotherapy system** around them. This system seamlessly integrates cutting-edge genomics, intelligent combination pharmacology, strategic clinical application, adaptive regulation, and scalable logistics. By doing so, the field can transform the immense scientific promise of anticancer vaccines into a widespread and transformative reality for patients, turning advanced cancers into manageable conditions and preventing recurrences in early-stage disease, thereby fundamentally changing the paradigm of cancer care (Lorentzen, C. L., Haanen, J. B., Met, Ö., & Svane, I. M. 2022).

SUGGESTIONS

Based on the comprehensive analysis of the scientific discourse surrounding anticancer vaccines, their innovations, pharmacology, clinical applications, and future perspectives, a set of strategic suggestions can be proposed to guide researchers, clinicians, industry stakeholders, and regulatory bodies. These suggestions aim to accelerate the development, optimize the deployment, and maximize the clinical impact of this transformative therapeutic modality.

For Research and Development: A primary suggestion is to intensify efforts in the neoantigen discovery and validation pipeline. Research should focus on refining bioinformatic algorithms to

improve the prediction of immunogenic neoantigens with high accuracy, moving beyond mere MHC-binding affinity to better predict T-cell receptor recognition and the actual capacity to elicit a functional immune response. Investment in high-throughput functional screening assays is crucial to experimentally validate these predictions, ensuring that selected epitopes are not just theoretical constructs but potent immunogens. Furthermore, research must delve deeper into the phenomenon of antigen loss variance. Developing strategies for vaccines that target multiple, essential neoantigens simultaneously or that are designed to induce broad immune responses against public neoantigens or shared cancer testis antigens could help prevent tumor escape and improve the durability of responses.

Concurrently, innovation in vaccine platform technology must continue. For mRNA vaccines, research should focus on next-generation lipid nanoparticles and other delivery systems that further enhance stability, delivery efficiency, and tissue specificity while potentially reducing reactogenicity. The development of self-amplifying mRNA constructs could also be explored to achieve more potent and sustained antigen expression at lower doses. For all platforms, a key suggestion is the systematic development and testing of novel, potent, yet well-tolerated adjuvants that can skew the immune response towards a robust and durable Th1-type and cytotoxic T-cell profile, effectively conditioning the immune microenvironment for a successful attack.

For Clinical Trial Design and Implementation: A critical suggestions for the clinical sector is to move beyond evaluating vaccines as monotherapies in advanced, treatment-refractory patients, a setting where single-agent efficacy is likely to be low. Future trials should be strategically designed to investigate vaccines in rational combinations from the outset. Priority should be given to combinations with immune checkpoint inhibitors, with a focus on optimizing sequencing, dosing, and scheduling to achieve maximal synergy. Trials combining vaccines with other immunomodulatory agents, such as cytokines, co-stimulatory agonists, or therapies that target the immunosuppressive tumor microenvironment (e.g., TGF-β inhibitors, IDO inhibitors), are also highly recommended.

Perhaps the most promising recommended shift is to prioritize clinical trials in the adjuvant and minimal residual disease settings. Following definitive local therapy like surgery or radiotherapy, the tumor burden is low, and the immune system is more capable of mounting an effective response. Vaccines administered in this context could prime the immune system to surveil and eliminate residual disseminated cells, preventing recurrence and potentially curing the disease. Trials in this setting should utilize overall survival and relapse-free survival as primary endpoints, as they are most relevant to the goal of long-term control.

To better capture the biological activity of vaccines, clinical trials must incorporate robust and standardized correlative studies. These should include deep immune monitoring of peripheral blood and, where feasible, paired tumor biopsies. Analysis should go beyond mere quantification of antigen-specific T cells to assess their functional quality, phenotype (e.g., memory subsets, exhaustion markers), TCR clonality, and ability to infiltrate the tumor post-vaccination. The identification of predictive biomarkers of response is paramount. Research should aim to define criteria such as optimal mutational burden, specific immune gene signatures, or baseline immune cell infiltration that can help select patients most likely to benefit from vaccine therapy, thereby increasing clinical trial efficiency and future treatment success rates.

For Regulatory and Manufacturing Considerations: Regulatory agencies must develop adaptive and streamlined pathways for the approval of personalized cancer vaccines. The traditional clinical trial model is challenging for bespoke therapies. Innovative trial designs, such as platform trials or basket trials that can evaluate a single vaccine platform across multiple cancer types based on a common biomarker (e.g., high tumor mutational burden), should be encouraged and accepted. Regulatory guidance must be established for the complex process of validating the entire chain of personalization, from sequencing and bioinformatics to manufacturing and release testing.

On the manufacturing front, there is an urgent need to invest in and develop scalable, automated, and cost-effective Good Manufacturing Practice (GMP) processes for personalized vaccine production. For mRNA-based neoantigen vaccines, this involves creating streamlined facilities capable of rapid in vitro transcription, formulation, and quality control to turn around a patient-specific product within a clinically relevant timeframe of weeks. Reducing the cost and complexity of manufacturing is essential to making these innovative therapies accessible beyond specialized academic centers. For off-the-shelf approaches targeting public neoantigens, the sugestion is to pursue large-scale manufacturing akin to traditional biologics, which would facilitate broader distribution and use.

For Clinical Integration and Education: As these therapies move towards broader clinical use, efforts must be made to educate a multidisciplinary team of oncologists, surgeons, pathologists, and nurses on the unique aspects of cancer vaccines. Understanding the mechanism of action, the management of potential immune-related adverse events, and the realistic expectations for clinical response—which may differ from the rapid tumor shrinkage seen with chemotherapy—is vital. The oncology community must also prepare for the logistical integration of personalized medicine, which requires close collaboration between the clinic, molecular pathology, bioinformatics, and pharmacy.

The promising field of anticancer vaccines stands at a pivotal juncture. By implementing these suggestions—prioritizing neoantigen research, embracing rational combination therapies in optimal clinical settings, adapting regulatory frameworks, revolutionizing manufacturing, and educating clinicians—the immense potential of these therapies to reshape cancer care and improve patient outcomes can be fully realized. The goal is to systematically translate scientific innovation into reliable, effective, and accessible treatments for patients worldwide.

CONCLUSIONS

The extensive scientific discourse on the development and application of anticancer vaccines culminates in a series of definitive conclusions that mark a paradigm shift in oncological therapy. This journey from theoretical concept to clinical reality underscores a transition from broad, non-specific cytotoxic treatments towards highly precise, personalized immunomodulation. The overarching conclusion is that anticancer vaccines have irrevocably established themselves as a legitimate and potent pillar within the broader armamentarium of immunotherapy, representing a sophisticated strategy to educate and mobilize the host's immune system against malignancy. A primary conclusion drawn from decades of research is the critical importance of antigen selection. The empirical evidence overwhelmingly affirms that targeting tumor-specific neoantigens, derived from somatic mutations unique to the individual's cancer, provides a superior therapeutic window compared to targeting shared tumor-associated antigens. This approach minimizes the risk of central tolerance and autoimmune sequelae while maximizing the potential for eliciting high-affinity, potent T-cell responses directed exclusively against the tumor. The success of neoantigen vaccines is a testament to the power of genomics and bioinformatics, demonstrating that the integration of large-scale sequencing data with predictive algorithms can yield viable and highly specific therapeutic targets. Consequently, the future of cancer vaccinology is inextricably linked to the principles of personalization, moving away from one-size-fits-all solutions towards bespoke therapies tailored to the unique mutational landscape of each patient's disease. By prioritizing sophisticated antigen selection, embracing combinatorial strategies in optimal clinical settings, revolutionizing regulatory and manufacturing frameworks, and preparing the healthcare workforce, the immense promise of anticancer vaccines can be translated into tangible and life-changing benefits for patients.

RECOMMENDATIONS

Based on the extensive scientific discourse, the development and integration of anticancer vaccines into mainstream oncology require a strategic and multi-faceted approach. The following

key recommendations are proposed to guide researchers, clinicians, industry, and regulatory bodies towards realizing the full potential of this transformative modality.

- **Research must prioritize the refinement of neoantigen prediction and vaccine platform technology.** Investment should focus on enhancing bioinformatic algorithms to move beyond predicting MHC-binding affinity towards accurately forecasting T-cell receptor recognition and immunogenicity. Concurrently, efforts must accelerate the development of next-generation delivery systems, such as improved lipid nanoparticles for mRNA vaccines that enhance stability, efficacy, and tissue specificity while minimizing reactogenicity. The exploration of novel, potent adjuvants capable of driving robust and durable Th1 and cytotoxic T-cell responses is equally critical.
- **Clinical trial design must evolve strategically.** The field should largely abandon evaluating vaccines as monotherapies in advanced, refractory disease, a setting where success is limited. Instead, priority must be given to **rational combination therapies**, particularly with immune checkpoint inhibitors, from the earliest stages of clinical development. Trials should meticulously optimize dosing, sequencing, and scheduling to achieve maximal synergy. Most importantly, a pivotal shift towards **adjuvant and minimal residual disease settings** is essential. Following surgery or chemotherapy, vaccine-induced immune surveillance has the greatest potential to eradicate residual cells, prevent recurrence, and improve cure rates. Trials in these settings should utilize relapse-free and overall survival as primary endpoints.
- **A revolution in regulatory and manufacturing paradigms is imperative.** Regulatory agencies must develop adaptive, streamlined pathways for approving personalized therapies, potentially embracing innovative trial designs like platform or basket trials. Simultaneously, massive investment is required to create **scalable, automated, and cost-effective manufacturing processes** for personalized vaccines. The goal is to reduce the complex, weeks-long production of bespoke therapies into a efficient, standardized clinical service, ensuring broader accessibility.
- Successful implementation hinges on **preparing the clinical ecosystem.** This necessitates educating a multidisciplinary team of oncologists, surgeons, pharmacists and pathologists on the unique aspects of cancer vaccines, including their mechanism of action, management of immune-related events, and realistic expectations for response. Establishing molecular tumor boards that include immunologists and bioinformaticians is crucial for patient selection and management.

REFERENCES

- Blass, E., & Ott, P. A. (2021). Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. *Nature Reviews Clinical Oncology, 18*
- (4), 215–229.
- Hu, Z., Leet, D. E., Allesøe, R. L., Oliveira, G., and et al (2021). Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. *Nature Medicine, 27* (3), 515–525.
- Sahin, U., & Türeci, Ö. (2018). Personalized vaccines for cancer immunotherapy. *Science, 359*(6382), 1355–1360.
- Ott, P. A., Hu-Lieskovan, S., Chmielowski, B., Govindan, R., Naing, A., and et al (2020). A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. *Cell, 183* (2), 347-362.
- Hilf, N., Kuttruff-Coqui, S., Frenzel, K., Bukur, V., and et al (2019). Actively personalized vaccination trial for newly diagnosed glioblastoma. *Nature, 565*(7738), 240–245.
- Miao, L., Zhang, Y., & Huang, L. (2021). mRNA vaccine for cancer immunotherapy. *Molecular Cancer, 20* (1), 41.
- Melero, I., Gaudernack, G., Gerritsen, W., Huber, C., and et al (2014). Therapeutic vaccines for cancer: An overview of clinical trials. *Nature Reviews Clinical Oncology, 11*(9), 509–524.
- Palucka, K., & Banchereau, J. (2023). Dendritic-cell-based therapeutic cancer vaccines. *Immunity, 39* (1), 38–48.
- Sulashvili, N., Gorgaslidze, N., Gabunia, L., Alavidze, N., Sulashvili, M. (2024). The scientific discussion of some issues of features and challenges of using of car-t cells in immunotherapy. Georgian Scientists, 6(4), 263–290.
- Saxena, M., van der Burg, S. H., Melief, C. J. M., & Bhardwaj, N. (2021). Therapeutic cancer vaccines. *Nature Reviews Cancer, 21* (6), 360–378.
- Tanyi, J. L., Bobisse, S., Ophir, E., Tuyaerts, S., and et al (2018). Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. *Science Translational Medicine, 10*(436), eaao5931.

- Vormehr, M., Türeci, Ö., & Sahin, U. (2019). Harnessing tumor mutations for truly individualized cancer vaccines. *Annual Review of Medicine, 70*, 395–407.
- Sulashvili, N., Abzianidze, E., Chichoyan, N., Zarnadze, S. (Davit). (2025). The manifestation of scientific discussion on new antiretroviral medicines: a comprehensive analysis of classification, clinical use, features, mechanisms, pharmacology and toxicities in general. Georgian Scientists, 7(3), 522–569.
- Yarchoan, M., Johnson, B. A., Lutz, E. R., Laheru, D. A., & Jaffee, E. M. (2022). Targeting neoantigens to augment antitumour immunity. *Nature Reviews Cancer, 17* (4), 209–222.
- Sulashvili, N., Abzianidze, E., Chichoyan, N., Zarnadze, S. (Davit). (2025). The manifestation of scientific aspects of classification, clinical use, features, mechanism of action, pharmacology, effects and toxicities of new anticancer drugs in general. Georgian Scientists, 7(3), 570–611.
- Keskin, D. B., Anandappa, A. J., Sun, J., Tirosh, I., and et al (2021). Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. *Nature, 565* (7738), 234–239.
- Lorentzen, C. L., Haanen, J. B., Met, Ö., & Svane, I. M. (2022). Clinical advances and future directions in cancer vaccines. *Journal of Internal Medicine, 292* (2), 191–208.
- Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018). mRNA vaccines — a new era in vaccinology. *Nature Reviews Drug Discovery, 17* (4), 261–279.